Global marketing and commercialization advances for Alvotech and partners

Home/Pharma News | Posted 27/01/2023 post-comment0 Post your comment

In late 2022 and early 2023, Alvotech announced several strategic partnership advances to further their global reach as a biotech company specializing in the development and manufacture of biosimilar medicines.

Business Aquisition V13F07

Specifically, these advances cover their partnership with Fuji Pharma Co in Japan, STADA in Europe and Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra GmbH, a Germany-based company in Africa and the Middle East. In all cases, products are developed and manufactured by Alvotech and marketed and commercialized by their partners. 

Alvotech-Fuji Pharma partnership
Together with partner Fuji Pharma Co, Alvotech is expanding their existing exclusive commercialization partnership that covers Japan, by adding a new undisclosed biosimilar candidate. The Alvotech-Fuji Pharma partnership was formed in 2018 [1] and then extended in 2020 [2] and 2022. The partnership now covers seven biosimilars including the new candidate. In October 2022, Alvotech-Fuji Pharma announced the submission of an application to the Japanese Ministry of Health, Labour and Welfare for marketing approval of the first biosimilar candidate developed under the companies’ partnership [3]. 

Alvotech-STADA partnership
In Europe, Alvotech and STADA are increasing the availability of high-quality biological treatments by rolling out their Hukyndra (adalimumab)  high-concentration, low-volume, citrate-free formulation of adalimumab in several European countries: Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania and Slovenia. This follows initial introduction of Hukyndra in nine other European countries: Austria, Estonia, Finland, France, Germany, Lithuania, Slovakia, Sweden and Switzerland. 

Hukyndra is also known as Libmyris [4] and the developmental name, AVT02.  

Adalimumab is a human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF); a soluble inflammatory cytokine. Adalimumab binds to TNF-alpha (TNF-α), preventing it from activating TNF receptors, which cause the inflammatory reactions associated with autoimmune diseases. Adalimumab is indicated for the treatment of rheumatoid, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis. The originator is AbbVie’s Humira [5].

Hukyndra is the first product launched through the exclusive Alvotech-STADA partnership first announced in November 2019 [3] covering biosimilar candidates across immunology, oncology and ophthalmology indications.

Alvotech-Bioventure-Minapharm-MiGenTra partnership
Alvotech has also signed an exclusive license agreement with Bioventure, Minapharm Pharmaceuticals and MiGenTra GmbH for the commercialization of multiple biosimilar candidates in Egypt and 18 additional countries in Africa and the Middle East. The partnership will now see the latter companies share the launching and marketing responsibilities of Alvotech manufactured biosimilars in these regions. All other terms and product details in the agreement currently remain confidential. 

Related articles
Alvotech and Celltrion proceed with adalimumab and rituximab biosimilars 

Alvotech and Cipla Gulf partnership announced

Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan 

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Alvotech makes deal with Fuji Pharma for biosimilars in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Partnerships formed and extended between Isu Abxis/Pharmasyntez and Alvotech/Fuji Pharma []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Advances for Alvotech’s partnerships in Japan, Canada and Switzerland []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of two adalimumab biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:
5. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010